A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Rotigotine (Neupro)

NEUPRO is a dopamine agonist indicated for the treatment of: Parkinson's disease ( 1.1 ) Moderate-to-severe primary Restless Legs Syndrome ( 1.2 ) 1.1 Parkinson's Disease (PD) NEUPRO is indicated f....

First FDA approval2012-04-02
Generic availableNo (brand-only)
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$128.5M in CY2024 Part D spend114K claims · 26K beneficiaries · 329 plans surveyed

Lowest NADAC
$28.21/unit
6 NDCs benchmarked, lowest of all strengths.
Average NADAC
$28.27
Across all dosage forms in distribution.
Highest NADAC
$28.30
Range is tight.
Plans with PA
18 / 329
Limited PA friction.

Questions a plan sponsor actually asks.

FAQPage schema11 entries indexed · 4 visible
What is Rotigotine used for?

NEUPRO is a dopamine agonist indicated for the treatment of: Parkinson's disease ( 1.1 ) Moderate-to-severe primary Restless Legs Syndrome ( 1.2 ) 1.1 Parkinson's Disease (PD) NEUPRO is indicated f....

Is there a generic for Rotigotine?

No. Rotigotine is brand-only with no generic equivalents currently in market.

How much does my plan pay for Rotigotine?

Across 329 Part D plans, Rotigotine averages $28.27/unit (NADAC). Lowest available: $28.21/unit. Highest in distribution: $28.30/unit.

Is Rotigotine on the FDA shortage list?

No. Rotigotine is not currently on the FDA Drug Shortage Database.

7 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Nonergot Dopamine Agonist2 alternatives in D1
01
Pramipexole Dihydrochloride
Nonergot Dopamine Agonist
$0.041Lowest NADAC
16Generic mfrs
CY24 Part D spend
Compare →
02
Ropinirole
Nonergot Dopamine Agonist
$0.043Lowest NADAC
13Generic mfrs
$97.6MCY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (6 approvals on file) · NADAC unit costs: CMS NADAC weekly file (6 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.